Skip to content
Open in App
AstraZeneca logo

AstraZeneca

web2

AstraZeneca PLC, a biopharmaceutical company, focuses on the discovery, development, manufactur...

Symbol · AZN
Company profile

About

AstraZeneca PLC, a biopharmaceutical company, focuses on the discovery, development, manufacture, and commercialization of prescription medicines. The company offers Imjudo, Datroway, Iressa, Tagrisso, Imfinzi, Lynparza, Calquence, Enhertu, Orpathys, Truqap, Zoladex, Faslodex, Crestor, Andexxa, Onglyza, Symlin, XIGDUO XR, Atacand, Atacand HCT, Atacand Plus, Farxiga/Forxiga, Plendil, Modip, Splendil, Munobal, Flodil, Tenormin, Tenormine, Prenormine, Atenol, Zestril, Brilinta/Brilique, Komboglyze, Qtern, Wainua, Byetta, Lokelma, Seloken ZOK, Toprol-XL, Betaloc ZOK, XIGDUO, Accolate, Accoleit, Vanticon, Bricanyl Respules, Eklira Genuair/Tudorza/Bretaris, Pulmicort Turbuhaler, Symbicort Turbuhaler, Airsupra, Bricanyl Turbuhaler, Fasenra, Rhinocort, Tezspire, Bevespi Aerosphere, Daliresp/Daxas, Oxis Turbuhaler, Saphnelo, Breztri Aerosphere, Duaklir Genuair, Pulmicort Respules, and Symbicort pMDI. It also provides Beyfortus, Kavigale, Evusheld, Fluenz/FluMist, Synagis, Kanuma, Ultomiris, Koselugo, Voydeya, Soliris, Strensiq, Nexium, and other medicines. The company offers its products for ocology, cardiovascular, renal and metabolism, respiratory & immunology, vaccines and immune, and therapies rare diseases. It serves primary and specialty care physicians through distributors and local representative offices in the United Kingdom, the Americas, rest of Europe, Asia, Africa, and Australasia. It has a strategic agreement with Tempus and Pathos to develop the largest multimodal foundation model in oncology; CSPC Pharmaceutical Group Limited to advance the discovery and development of novel oral candidates, with the potential to treat diseases across multiple indications; and Nucs AI Inc. to develop AI-driven Response Prediction for Therapeutic Radioconjugates. The company was formerly known as Zeneca Group PLC and changed its name to AstraZeneca PLC in April 1999. AstraZeneca PLC was incorporated in 1992 and is headquartered in Cambridge, the United Kingdom.

Explore by sector

Explore this sector

Presentation

Watch AstraZeneca

Market identity

Exchange listings

Listing identities only. Orbitrum does not publish live prices or market performance on this public profile.

Progress

Roadmap

Tozorakimab meets primary endpoint in two Phase III COPD trials

KEY STEP

AstraZeneca announced positive high level results from the OBERON and TITANIA Phase III trials. Tozorakimab reduced annualised moderate to severe COPD exacerbations versus placebo in the primary population of former smokers and in the broader overall population, while showing a favourable safety profile.

Roadmap reference

Enhertu receives two US approvals in HER2 positive early breast cancer

KEY STEP

The US FDA approved Enhertu for two new HER2 positive early breast cancer indications. The first covers treatment before surgery for adults with Stage II or Stage III disease using Enhertu followed by taxane, trastuzumab and pertuzumab. The second covers treatment after surgery for adults with residual invasive disease following trastuzumab based and taxane based treatment. The approvals were supported by the Phase III DESTINY Breast11 and DESTINY Breast05 trials.

Roadmap reference
People

Company team

BM

Birgit M. Conix

Non-Executive Director

Company leadership profile.

MR

Michel Roger Demare

Independent Chairman

Company leadership profile.

PC

Pascal Claude Roland Soriot

CEO & Executive Director

Company leadership profile.

AS

Aradhana Sarin

CFO & Executive Director

Company leadership profile.

PP

Pam P. Cheng

EVP of Global opt. & IT, Chief Sust. Officer and Member of External Sust.Adv. Board

Company leadership profile.

JP

Jeffrey Pott

CHRO, Chief Compliance Officer, General Counsel & Member of External Sustainability Advisory Board

Company leadership profile.

PA

Philip Arthur John Broadley

Senior Independent Non-Executive Director

Company leadership profile.

SS

Sherilyn S. Dawn McCoy

Independent Non-Executive Director

Company leadership profile.

SK

Shu Kam Mok

Independent Non-Executive Director

Company leadership profile.

MW

Marcus Wallenberg

Non-Executive Director

Company leadership profile.

EA

Euan Angus Ashley

Independent Non-Executive Director

Company leadership profile.

DL

Diana Louise Patricia Layfield

Independent Non-Executive Director

Company leadership profile.

PB

Pankaj Bhatia

Member of External Sustainability Advisory Board

Company leadership profile.

DV

Dame Veronica Anne Courtice

Member of External Sustainability Advisory Board

Company leadership profile.

LN

Louise Nicholls

Member of External Sustainability Advisory Board

Company leadership profile.

RH

Rain Henderson

Member of External Sustainability Advisory Board

Company leadership profile.

AO

Anna Olive Magdelene Manz

Non-Executive Director

Company leadership profile.

KE

Karen Elizabeth Knudsen

Non-Executive Director

Company leadership profile.

Expert coverage

2 experts evaluated AstraZeneca.

Orbitrum research

Experts evaluating AstraZeneca

Explore the public profiles of experts who have evaluated this project.

Orbitrum Academy

Learn how to read a project assessment